Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hesketh

Showing results (231-240 of 248) with videos related to

Pageof 25
Sort By:
Journal of Oncology Practice|October 6, 2017
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible PatientsThomas J Smith, Nasser Hanna, David Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2017
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdatePaul J Hesketh, Mark G Kris, Ethan Basch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patientsF Roila, A Molassiotis, J Herrstedt, et al.
Plos One|November 28, 2018
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLCMichael E Goldberg, Meagan Montesion, Lauren Young, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementEdward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2010
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceF Roila, J Herrstedt, M Aapro, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
Cell Reports|May 31, 2024
A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4<sup>+</sup> T cell activationSarah Hulin-Curtis, James K Geary, Bruce J MacLachlan, et al.
Practical Radiation Oncology|June 9, 2023
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice GuidelinePuneeth Iyengar, Sean All, Mark F Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline UpdateNasser H Hanna, Bryan J Schneider, Sarah Temin, et al.
Pageof 25

Showing results (231-240 of 248) with videos related to

Sort By:
Pageof 25
Journal of Oncology Practice|October 6, 2017
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible PatientsThomas J Smith, Nasser Hanna, David Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2017
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdatePaul J Hesketh, Mark G Kris, Ethan Basch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patientsF Roila, A Molassiotis, J Herrstedt, et al.
Plos One|November 28, 2018
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLCMichael E Goldberg, Meagan Montesion, Lauren Young, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementEdward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2010
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceF Roila, J Herrstedt, M Aapro, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
Cell Reports|May 31, 2024
A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4<sup>+</sup> T cell activationSarah Hulin-Curtis, James K Geary, Bruce J MacLachlan, et al.
Practical Radiation Oncology|June 9, 2023
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice GuidelinePuneeth Iyengar, Sean All, Mark F Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline UpdateNasser H Hanna, Bryan J Schneider, Sarah Temin, et al.
Pageof 25